Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...
TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...
Johnson & Johnson (JNJ) has been one of the great health care and consumer products survivors of our lifetimes. Even the latest round of over-the-counter quality control flaws did not cripple the ...
SAN FRANCISCO, May 19, 2009 – Schizophrenia is one of the most disabling diseases, and frequent relapses and rehospitalization as a result of the disease place enormous burdens on patients, caregivers ...
SAN FRANCISCO, May 19, 2009 – New data demonstrate that maintenance therapy with RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to ...
Risperidone 12.5mg, 25mg, 37.5mg, 50mg; per vial; pwd for long-acting IM inj after reconstitution. Risperidone-naive: rule out risperidone hypersensitivity before using injection. Give by deep deltoid ...
Sept. 19, 2005 — The European Commission has approved exemestane tablets for the treatment of estrogen receptor–positive invasive early breast cancer after two to three years of initial adjuvant ...
May 27, 2009 — The US Food and Drug Administration (FDA) has approved risperidone long-acting injection for use alone or with lithium or valproate in the treatment of bipolar I disorder; and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results